This site is intended for healthcare professionals
Journals
  • Home
  • /
  • Journals
  • /
  • Multiple sclerosis
  • /
  • Therapeutic Advances in Multiple Sclerosis
Journal

Therapeutic Advances in Multiple Sclerosis

Read time: 1 mins
Published:3rd Jun 2022
Author: Yang JH, Rempe T, Whitmire N, Dunn-Pirio A, Graves JS.
Availability: Free full text
Ref.:Front Neurol. 2022 Jun 3;13:824926.
DOI:10.3389/fneur.2022.824926
Therapeutic Advances in Multiple Sclerosis


Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that causes significant disability and healthcare burden. The treatment of MS has evolved over the past three decades with development of new, high efficacy disease modifying therapies targeting various mechanisms including immune modulation, immune cell suppression or depletion and enhanced immune cell sequestration. Emerging therapies include CNS-penetrant Bruton's tyrosine kinase inhibitors and autologous hematopoietic stem cell transplantation as well as therapies aimed at remyelination or neuroprotection. Therapy development for progressive MS has been more challenging with limited efficacy of current approved agents for inactive disease and older patients with MS. The aim of this review is to provide a broad overview of the current therapeutic landscape for MS.


Read abstract on library site  Access full article